GLP-3RTA is a synthetic research peptide studied for triple hormone receptor agonism — activity across the GLP-1, GIP, and glucagon receptors within a single molecule. That three-receptor mechanism has made it one of the most closely watched areas of metabolic and endocrine research, setting it apart from single- or dual-agonist peptides such as Semaglutide and GLP-1TRZ. Helix Bio supplies GLP-3RTA as a lyophilized powder intended strictly for laboratory and preclinical research, manufactured to a high-purity standard and backed by third-party verification. It is not intended for human consumption, diagnostic use, or any therapeutic application.
HPLC certified
Independent analysis
Highest standard
Full traceability
GLP-3RTA belongs to a newer class of incretin-based peptides studied for activity across three separate metabolic receptor pathways rather than one or two. Earlier compounds such as liraglutide and semaglutide act on the GLP-1 receptor alone, and GLP-1TRZ adds GIP receptor activity on top of that. GLP-3RTA is studied for engaging GLP-1, GIP, and glucagon receptors concurrently — the "triple agonist" profile that draws so much attention from researchers working on metabolic rate, appetite regulation, and glucose homeostasis models.
Helix Bio's GLP-3RTA is supplied as a lyophilized (freeze-dried) powder — a single-chain synthetic peptide manufactured under controlled laboratory conditions. Lyophilization extends the peptide's shelf stability prior to reconstitution, which matters for labs that don't use a full vial in one sitting.
This product exists to support in vitro and preclinical laboratory research only. It's manufactured, labeled, and sold for research use only (RUO) — not for human or veterinary use, not for diagnostic procedures, and not for compounding. It's intended for researchers studying incretin pharmacology, receptor binding behavior, or metabolic research models.
Sourcing a research peptide comes down to trust — trust in what's actually in the vial, trust in the paperwork behind it, and trust that the supplier understands the compound well enough to represent it accurately. GLP-3RTA is a molecule researchers are watching closely right now, precisely because its three-receptor mechanism sets it apart from the GLP-1-only and dual-agonist peptides that have dominated metabolic research for years. Helix Bio manufactures its GLP-3RTA domestically, backs every batch with purity testing, and provides documentation so researchers can evaluate what they're working with before it reaches the bench. If your protocol calls for a triple agonist peptide with a clear paper trail, that's what this listing is built around.
This product is not intended for individual consumers seeking to use it outside a research setting.
| Field | Detail |
|---|---|
| Product Name | GLP-3RTA |
| Category | Research Peptide — Triple GLP-1 / GIP / Glucagon Receptor Agonist |
| Form | Lyophilized powder |
| Purity | High-purity, batch-verified — see current lot's Certificate of Analysis for the exact figure |
| Appearance | White to off-white lyophilized powder |
| Storage (unreconstituted) | Store frozen, protected from light |
| Packaging | Sealed glass vial, tamper-evident packaging |
| Research Use | Laboratory / in vitro / preclinical research only — not for human or animal use |
| Manufacturer | Domestically produced (USA) |
| Quality | Third-party purity testing performed per batch |
| Lot Testing | HPLC and mass spectrometry verification |
| Country of Origin | United States |
GLP-3RTA is studied across a few overlapping areas of metabolic and endocrine research:
As of mid-2026, Eli Lilly's Phase 3 TRIUMPH program and a separate Phase 3 diabetes program (TRANSCEND-T2D-1) have both published topline results for triple-agonist compounds, giving researchers a growing body of clinical-stage data to reference alongside earlier Phase 1 and Phase 2 findings. Triple hormone receptor agonists remain investigational — GLP-3RTA is not FDA-approved and is not available by prescription. Everything sold by Helix Bio is intended for laboratory research only, not for administration to humans or animals outside a licensed research setting.
Purity is the first thing serious researchers check, and it's the first thing worth being transparent about. Helix Bio's GLP-3RTA is manufactured in a controlled laboratory environment and tested by a third party using high-performance liquid chromatography (HPLC) and mass spectrometry — the two standard methods for confirming peptide identity and purity in the research supply chain. Each batch is issued its own Certificate of Analysis (COA), so purity isn't something you have to take on faith; you can review the documentation for the specific lot you receive. If a vendor can't produce a COA for the batch in your hand, that's worth treating as a red flag — for GLP-3RTA or any research peptide.
Handling in our facility follows accepted good manufacturing practice for research-use compounds: peptides are processed to limit contamination, packaged in sealed, tamper-evident vials, and shipped in a way that protects the lyophilized powder from temperature swings and light exposure during transit.
GLP-3RTA ships in a sealed, tamper-evident vial packaged to protect the lyophilized powder in transit. Because peptide stability can be affected by heat, orders are packed with insulation appropriate to the season and route. Exact carriers, transit times, and packaging materials can vary by order — check Helix Bio's shipping policy page for current specifics before ordering.
GLP-3RTA sold by Helix Bio is intended strictly for in vitro laboratory and preclinical research use. It is not a drug, dietary supplement, cosmetic, or food product, and it is not approved by the FDA or any regulatory body for human or veterinary use, diagnosis, treatment, cure, or prevention of any disease or condition. This product must not be administered to humans or animals outside of a properly licensed research facility. Nothing on this page constitutes medical advice, and no statement here should be interpreted as a therapeutic or health claim. By purchasing this product, the buyer confirms they are a qualified researcher, laboratory, or institution acquiring it for lawful research purposes only, and accepts full responsibility for compliance with all applicable local, state, and federal regulations governing research chemicals.
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Amycretin is a peptide and orforglipron is not. How that chemistry explains the formulations, trial results, and approval status of both GLP-1 pills.
Five peptide sellers got FDA warning letters in September 2026. See who was named, why the research label failed, and the full 2026 enforcement timeline.
In July 2026, the FDA's advisory committee recommended 6 peptides for the 503A bulk list. None are on it yet. What the vote changed and what it didn't.
